Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial
Shuo Luan,Shaoling Wang,Caina Lin,Shengnuo Fan,Cuicui Liu,Chao Ma,Shaoling Wu
DOI: https://doi.org/10.2147/JPR.S347961
IF: 2.8319
2022-02-05
Journal of Pain Research
Abstract:Shuo Luan, &ast Shaoling Wang, &ast Caina Lin, Shengnuo Fan, Cuicui Liu, Chao Ma, Shaoling Wu Department of Rehabilitation Medicine, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, 510120, Guangdong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shaoling Wu; Chao Ma, Email ; Background and Objective: Osteonecrosis of the femoral head (ONFH) is a devastating disease, and there is some evidence that extracorporeal shock wave therapy (ESWT) and intra-articular platelet-rich plasma (PRP) injection might alleviate pain and improve joint function in individuals with ONFH. The objective of this study was to compare the effectiveness and safety of PRP and ESWT in symptomatic ONFH patients. Methods: A total of 60 patients aged 40– 79 with unilateral ONFH at Association Research Circulation Osseous (ARCO) stages I, II, and III were randomly assigned to the PRP (N=30) or the ESWT group (N=30). Four treatment sessions were provided in both groups. Assessments were performed at baseline, and 1-, 3-, 6-, and 12-month. Primary outcomes were measured by the visual analogue scale (VAS), and pressure pain thresholds (PPTs). Secondary outcomes were assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Harris Hip Score (HHS), and magnetic resonance imaging (MRI). The linear mixed-model analysis was used to evaluate the differences between groups and within groups and the "group by time" interaction effects. Results: There were significant differences between groups in terms of changes over time for VAS, PPTs, WOMAC, and HHS since 3-month and maintained up to 12-month (P< 0.05, except for PPTs at 12-month). The simple main effects showed that the patients in PRP group had greater improvements in VAS (mean difference = − 0.82, 95% CI [− 1.39, − 0.25], P=0.005), WOMAC (mean difference = − 4.19, 95% CI [− 7.00, − 1.37], P=0.004), and HHS (mean difference = 5.28, 95% CI [1.94, 8.62], P=0.002). No related adverse events were reported. Conclusion: This study supported the effectiveness and safety of both the PRP injection and ESWT in treating ONFH patients. For symptomatic patients with ONFH, intra-articular PRP injection appeared superior to ESWT in pain relief and functional improvement. Keywords: necrosis of the femoral head, platelet-rich plasma, ultrasound-guided intra-articular injection, extracorporeal shock wave therapy Osteonecrosis of the femoral head (ONFH) may lead to progressive pain, hip joint dysfunction, and severely decreased life quality, affecting more and more patients worldwide. The aetiologies of ONFH are multifactorial and complicated, including both traumatic and non-traumatic (corticosteroid use, alcohol consumption, smoking, and genetic) causes. 1–3 Histopathological changes of ONFH are usually characterized by osteocytes death and empty lacunae in the osseous matrix, which further develops into low bone mass, and subchondral trabecular collapse. 4 Among the various diagnostic imaging examinations, MRI remains the most important diagnostic method with relatively high sensitivity and specificity, especially for patients with early-stage ONFH. The latest version of the Association Research Circulation Osseous (ARCO) classification system was revised in 2019, which has been proposed as one of the most popular classification systems for ONFH worldwide. 5 In particular, not all avascular bone necrosis shares the same causes. For example, the possible correlation between the tyrosine kinase inhibitors, immunosuppressants, monoclonal antibodies, rapamycin inhibitors, and selective estrogen receptor modulators, and osteonecrosis of the jaws should be highlighted. 6 Up to now, there are still no unified guidelines or recommendations for ONFH treatment, especially for patients accompanied by varying levels of pain symptoms. It is well accepted that patients with ARCO stage I and II were at early stages, with ARCO stage III and IV disease at late stages. 7 For patients with early-stage ONFH, joint-preserving procedures are recommended, including both the non-surgical options (drugs, extracorporeal shock wave, and biologic treatment) and surgical options (core decompression, vascularized bone graft, and so on). 8–10 Core decompression (CD) helps reduce the pressure in the femoral head, opens up the hardening zone, and further enhances the new bone regeneration. 11 Total hip arthroplasty (THA) remains the most widespread and the only definitive procedure for end-stage ONFH patients. 12 However, ONFH occurs predominantly in younger patients who are generally physically active and inclined to preserve the structural integ -Abstract Truncated-
clinical neurology